Major Parkinson's Study Launched
Espoo - “Dyskinesias often become a serious problem for people with Parkinson's disease. Delaying the onset of these motor complications would therefore offer a real improvement in the quality of life for patients and their families,” said Mary Baker, President of the European Parkinson's Disease Association (EPDA), UK. She welcomed the major study STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation) in Parkinson's disease (PD), which was recently launched by Orion Pharma, a joint business division of Orion Corporation and Novartis.
This study seeks to investigate whether - when used as initial therapy - the optimized Levodopa medication Stalevo, which contains Levodopa, Carbidopa and Entacapone, delays the onset of motor complications, such as dyskinesias, compared with the traditional formulation of Levodopa/Carbidopa. STRIDE-PD will enroll some 740 patients at 70 centres in 14 countries: Austria, Belgium, Canada, France, Finland, Germany, Greece, Italy, Spain, Sweden, Turkey, Switzerland, the United Kingdom and the USA. The first study results are expected in 2007. “If the study shows that Stalevo is superior to the traditional therapy up to the time of onset of dyskinesias, this could change the current treatment paradigm completely,” said Werner Poewe, Chair of the Depart-ment of Neurology at Innsbruck University, Austria. “We would then use Stalevo from the first day in patients needing Levodopa treatment.”
Levodopa is the most effective and most widely used symptomatic PD treatment for nearly 40 years. However, after several years of treatment with Levodopa, patients often begin to experience motor complications, such as “wearing-off” (when the effect of one dose of medication does not last until the next scheduled dose) and dyskinesias.